23February

Notice for the Annual General Meeting of Novo Nordisk A/S ... Read more

22February

Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with or ... Read more

09February

Novo Nordisk A/S: Ozempic® (semaglutide) approved in the EU for the treatment of ... Read more

08February

Novo Nordisk files annual report with the SEC ... Read more

23February

Notice for the Annual General Meeting of Novo Nordisk A/S ... Read more

22February

Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with or ... Read more

19February

Novo Nordisk A/S - Share repurchase programme ... Read more

13February

Trading in Novo Nordisk shares by board members, executives and associated perso ... Read more

28February

Credit Suisse Healthcare conference, London

13March

Barclays Global Healthcare Conference, Miami

15March

Carnegie's Nordic Healthcare Seminar, Stockholm

22March

Annual General Meeting, Copenhagen

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

 
Annual Report 2017 


Click here to find further information

 
FY 2017 financial results


Novo Nordisk at a glance


Private shareholders


See relevant content for private investors



IR material


Download relevant Investor Relations material



Contacts



Subscriptions


Sign up to receive company announcements.


Ozempic® US approval


Link to conference call and presentation